Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chung-Han Lee

Showing results (61-70 of 101) with videos related to

Pageof 11
Sort By:
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
The Lancet. Oncology|July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trialLaurence Albiges, Howard Gurney, Vagif Atduev, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint BlockadeYasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer|October 21, 2023
Genomic ancestry in kidney cancer: Correlations with clinical and molecular featuresRitesh R Kotecha, Andrea Knezevic, Kanika Arora, et al.
Urologic Oncology|December 22, 2023
Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinomaStephen W Reese, Lennert Eismann, Charlie White, et al.
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Pageof 11

Showing results (61-70 of 101) with videos related to

Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|June 24, 2020
DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapyYasser Ged, Joshua L Chaim, Renzo G DiNatale, et al.
The Lancet. Oncology|July 14, 2023
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trialLaurence Albiges, Howard Gurney, Vagif Atduev, et al.
JCO Precision Oncology|September 11, 2020
Comprehensive Genomic Analysis of Metastatic Non-Clear-Cell Renal Cell Carcinoma to Identify Therapeutic TargetsMaria I Carlo, Nabeela Khan, Ahmet Zehir, et al.
European Urology|October 19, 2024
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
European Urology|May 23, 2024
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 TrialKelly N Fitzgerald, Chung-Han Lee, Martin H Voss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2022
Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint BlockadeYasser Ged, Alejandro Sanchez, Sujata Patil, et al.
Cancer|October 21, 2023
Genomic ancestry in kidney cancer: Correlations with clinical and molecular featuresRitesh R Kotecha, Andrea Knezevic, Kanika Arora, et al.
Urologic Oncology|December 22, 2023
Surgical outcomes of cytoreductive nephrectomy in patients receiving systemic immunotherapy for advanced renal cell carcinomaStephen W Reese, Lennert Eismann, Charlie White, et al.
European Urology|August 6, 2020
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial CarcinomaMin Yuen Teo, Jose Mauricio Mota, Karissa A Whiting, et al.
European Urology Oncology|November 9, 2023
A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney CancerRitesh R Kotecha, Sahil D Doshi, Andrea Knezevic, et al.
Pageof 11